AMD

APL-2 slows growth of GA in phase II safety and efficacy trialTwelve-month results of the FILLY trial show that in patients with geographic atrophy, the administration of complement C3 inhibitor APL-2 slowed the growth rate of the disease. It also appeared to increase the risk of new onset AMD, although this did not have an adverse effect on visual outcomes.
Latest research brings awareness to new AMD discoveriesResearch on treatments and/or causes of age-related macular degeneration (AMD) covers a wide range of approaches and paradigms. The latest research published in the past three months are perfect examples for understanding and treating AMD.
Most-talked-about journal articles bring ‘awareness’ to AMDTwo of the top 10 “most-talked-about” articles in JAMA Ophthalmology are about age-related macular degeneration (AMD). One of the current top 5 “most-read” articles in the American Journal of Ophthalmology is also about AMD. Here are a brief synopsis of those three papers.
AAO practice patterns offers ‘awareness’ to proper AMD treatmentThe American Academy of Ophthalmology’s Preferred Practice Pattern on Age-Related Macular Degeneration “are based on the best available scientific data as interpreted by panels of knowledgeable health professionals.” These patterns offer solid clinical guidelines for treating and counseling AMD patients.
Are you aware of the available resources for AMD?Since February is designated Age-Related Macular Degeneration Awareness month. For healthcare providers, there are numerous resources available to help promote awareness to patients and to encourage patients to continue (or start) annual visual exams.
Greater subfoveal choroidal thickness in AMD eyes; more injections needed
Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
Role of corticosteroids uncertain in AMD managementThere is no doubt that inflammation is a component of age-related macular degeneration (AMD), and yet the role of corticosteroid treatment in the management of eyes with AMD remains uncertain, said Marc de Smet, MD, PhD.
Ultra-widefield camera captures images from macula, far peripheryA recently released ultra-widefield fundus camera takes images in true color and captures high-resolution imagess rom the macula to the far periphery.
var script= ' ';